Last reviewed · How we verify
Histalog (BETAZOLE)
Histalog (BETAZOLE) is a small molecule betazole drug that targets the histamine H2 receptor. It is used for the stimulated gastric secretory test, but its commercial status is off-patent with no active Orange Book patents. Histalog works by blocking the histamine H2 receptor, which reduces gastric acid secretion. As an off-patent drug, it is not commercially available from generic manufacturers. Key safety considerations are not well-documented due to the lack of FDA approval and available information.
At a glance
| Generic name | BETAZOLE |
|---|---|
| Drug class | betazole |
| Target | Histamine H2 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Stimulated gastric secretory test
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Histalog CI brief — competitive landscape report
- Histalog updates RSS · CI watch RSS